E-MTAB-3218 - Biopsies from metastatic Clear Cell Renal Carcinoma before or after treatment with nivolumab
Submitted on 21 March 2014, released on 15 May 2016, last updated on 16 May 2016
Tumor core needle biopsies from kidney or metastatic sites obtained at trial enrollment i.e. Screen and/or at Cycle 2 Day 8 (i.e.Week 4) from metastatic clear cell RCC patients treated with 0.2mpk, 3mpk or 10mpk (as 2nd or further line of therapy; Arms A,B,C) or 10mpk (as first line therapy; Arm D) of nivolumab (BMS-936558,MDX-1106) on Bristol-Myers Squibb clinical trial protocol CA209-009.
transcription profiling by array, clinical history design, compound treatment design, time series design
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Toni K. Choueiri1,*, Mayer Fishman2, Bernard Escudier3, David F. McDermott4, Charles G. Drake5, Harriet M Kluger6, Walter M Stadler7, Jose Luis Perez-Gracia8, Douglas G McNeel9, Brendan D Curti10, Michael R. Harrison11, Elizabeth R. Plimack12, Leonard Appleman13, Lawrence Fong14, Laurence Albiges15, Lewis J. Cohen16, Tina C Young17, Scott D. Chasalow18, Petra Ross-MacDonald19, Shivani Srivastava20, Maria Jure-Kunkel21, John F Kurland22, Jason S Simon23, and Mario Sznol24. Clinical Cancer Research (2016)